NasdaqCM - Delayed Quote USD

Polyrizon Ltd. (PLRZ)

10.75 +1.75 (+19.40%)

At close: October 30 at 4:00:01 PM EDT

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker

GlobeNewswire 4d ago

PLRZ
+19.40%
Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform

GlobeNewswire 26d ago

PLRZ
+19.40%
Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement

GlobeNewswire 1mo ago

PLRZ
+19.40%
Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement

GlobeNewswire 1mo ago

PLRZ
+19.40%
Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study

GlobeNewswire 1mo ago

PLRZ
+19.40%
Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ)

InvestorsHub 3mo ago

PLRZ
+19.40%
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial

GlobeNewswire 3mo ago

PLRZ
+19.40%
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial

GlobeNewswire 4mo ago

PLRZ
+19.40%
Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology

GlobeNewswire 4mo ago

PLRZ
+19.40%
Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial

GlobeNewswire 4mo ago

PLRZ
+19.40%
Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial

GlobeNewswire 5mo ago

PLRZ
+19.40%
Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform

GlobeNewswire 5mo ago

PLRZ
+19.40%

Performance Overview

Return	PLRZ	S&P 500 (^GSPC)
YTD	+26.62%	+10.73%
1-Year	+73.95%	+11.11%
3-Year	-99.56%	+81.91%

U.S. markets closed

Polyrizon Ltd. (PLRZ)

Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker

Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform

Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement

Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement

Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study

Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ)

Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial

Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial

Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology

Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial

Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial

Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform